Skip to main content

Table 3 Change in patient-reported outcomes – overall study period

From: Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain

Instrument

LS Mean Change

Placebo

ALO-02

Differencea

p-value

Short Form-36v2 Health Survey

 Physical Functioning

5.32

6.84

1.52

0.1731

 Role-Physical

5.68

6.78

1.10

0.3290

 Bodily Pain

6.39

8.78

2.39

0.0232

 General Health

1.28

1.07

−0.20

0.8139

 Vitality

3.46

3.01

−0.45

0.6878

 Social Functioning

3.58

5.57

2.00

0.0658

 Role-Emotional

0.99

1.22

0.23

0.8670

 Mental Health

0.09

0.47

0.37

0.7259

 Physical Component Score

6.42

8.09

1.67

0.0989

 Mental Component Score

−0.44

−0.45

0.00

0.9969

EuroQol 5-Dimensions-3 Level

 Summary Index

0.085

0.106

0.021

0.2280

 Visual Analog Scale

4.75

7.01

2.26

0.2701

Work Productivity and Activity Impairment Questionnaire: Specific Health Problem

 Percentage work time missed due to low back pain

−1.00

−2.09

−1.09

0.7480

 Percentage impairment while working due to low back pain

−16.18

−25.38

−9.20

0.0581

 Percentage overall work impairment due to low back pain

−15.16

−25.51

−10.35

0.0679

 Percentage activity impairment due to low back pain

−18.62

−26.81

−8.19

0.0040

  1. ALO-02 extended-release oxycodone and sequestered naltrexone, LS least squares
  2. aDifference calculated as ALO-02 minus placebo; a positive difference favors ALO-02 and a negative difference favors placebo for SF-36v2 and EQ-5D-3L; a negative difference favors ALO-02 for WPAI:SHP